drugset
drugset / Trial / NCT00638976

INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

NCT00638976 ↗

Phase 3 Completed 91 enrolled Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
RandomizedParallel-groupSingle-blindSupportive care

Summary

Randomized, blind controlled, Multicenter, spontaneous, prospective trial, roughly 20 enrolling centers in Italy, placebo and active drug supply given by GlaxoSmithKline (GSK).

Timeline

Start
2007-11
Primary completion
2010-02
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eptifibatide Other / unclassified 2 ug/kg Intravenous

Indications

cardiovascular disorder